4.7 Article

ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer

期刊

BLOOD
卷 117, 期 26, 页码 7079-7089

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-12-317990

关键词

-

资金

  1. National Health and Medical Research Council of Australia
  2. Australian Research Council
  3. Leukemia Foundation
  4. Viertel Foundation
  5. Ramaciotti Foundation
  6. Cancer Institute of New South Wales
  7. Cancer Council New South Wales
  8. Israel Science Foundation
  9. Waxman Foundation
  10. Children with Leukemia United Kingdom
  11. Leukemia Research Foundation Chicago
  12. European Hematology Association
  13. Medical Research Council
  14. Leukemia & Lymphoma Research United Kingdom
  15. Biotechnology and Biological Sciences Research Council [BB/I00050X/1] Funding Source: researchfish
  16. Medical Research Council [G0800784B, G0800784] Funding Source: researchfish
  17. National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) [G0900729/1] Funding Source: researchfish
  18. BBSRC [BB/I00050X/1] Funding Source: UKRI
  19. MRC [G0800784] Funding Source: UKRI

向作者/读者索取更多资源

The Ets-related gene (ERG) is an Ets-transcription factor required for normal blood stem cell development. ERG expression is down-regulated during early T-lymphopoiesis but maintained in T-acute lymphoblastic leukemia (T-ALL), where it is recognized as an independent risk factor for adverse outcome. However, it is unclear whether ERG is directly involved in the pathogenesis of T-ALL and how its expression is regulated. Here we demonstrate that transgenic expression of ERG causes T-ALL in mice and that its knockdown reduces the proliferation of human MOLT4 T-ALL cells. We further demonstrate that ERG expression in primary human T-ALL cells is mediated by the binding of other T-cell oncogenes SCL/TAL1, LMO2, and LYL1 in concert with ERG, FLI1, and GATA3 to the ERG +85 enhancer. This enhancer is not active in normal T cells but in transgenic mice targets expression to fetal liver c-kit(+) cells, adult bone marrow stem/progenitors and early CD4(-)CD8(-) double-negative thymic progenitors. Taken together, these data illustrate that ERG promotes T-ALL and that failure to extinguish activity of stem cell enhancers associated with regulatory transcription factors such as ERG can contribute to the development of leukemia. (Blood. 2011;117(26):7079-7089)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Hematology

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy

Annatina S. Schnegg-Kaufmann, Julie A. I. Thoms, Golam Sarower Bhuyan, Henry R. Hampton, Lachlin Vaughan, Kayleigh Rutherford, Purvi M. Kakadia, Hui Mei Lee, Emma M. V. Johansson, Timothy W. Failes, Greg M. Arndt, Jason Koval, Robert Lindeman, Pauline Warburton, Alba Rodriguez-Meira, Adam J. Mead, Ashwin Unnikrishnan, Sarah Davidson, Mark N. Polizzotto, Mark Hertzberg, Elli Papaemmanuil, Stefan K. Bohlander, Omid R. Faridani, Christopher J. Jolly, Fabio Zanini, John E. Pimanda

Summary: Myelodysplastic neoplasms (MDSs) and chronic myelomonocytic leukemia (CMML) are clonal disorders driven by acquired somatic mutations. Hypomethylating agents (HMAs) can modify the clinical course of these diseases. Clinical improvement may be related to improved differentiation capacity of mutated hematopoietic stem cells.
Article Oncology

Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy

Laurence C. Cheung, Carlos Aya-Bonilla, Mark N. Cruickshank, Sung K. Chiu, Vincent Kuek, Denise Anderson, Grace-Alyssa Chua, Sajla Singh, Joyce Oommen, Emanuela Ferrari, Anastasia M. Hughes, Jette Ford, Elena Kunold, Maria C. Hesselman, Frederik Post, Kelly E. Faulk, Erin H. Breese, Erin M. Guest, Patrick A. Brown, Mignon L. Loh, Richard B. Lock, Ursula R. Kees, Rozbeh Jafari, Sebastien Malinge, Rishi S. Kotecha

Summary: In infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL), hypomethylating agents combined with most conventional chemotherapeutic agents showed additive effects in vitro, but antagonistic effects were observed in a subset of samples. Single agent treatment with azacitidine and decitabine significantly prolonged in vivo survival in KMT2A-rearranged infant ALL xenografts. Differential genome-wide DNA methylation, changes in gene expression, and thermal proteome profiling were observed in KMT2A-rearranged infant ALL cell lines treated with azacitidine and decitabine. The selective BCL-2 inhibitor, venetoclax, exhibited in vitro additivity when combined with hypomethylating or conventional chemotherapeutic agents. Addition of venetoclax to azacitidine resulted in a significant in vivo survival advantage, indicating the therapeutic potential of this combination in improving outcomes for infants with KMT2A-rearranged ALL.

LEUKEMIA (2023)

Article Hematology

STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia

Cedric S. Tremblay, Jesslyn Saw, Jacqueline A. Boyle, Katharina Haigh, Veronique Litalien, Hannah McCalmont, Kathryn Evans, Richard B. Lock, Stephen M. Jane, Jody J. Haigh, David J. Curtis

Summary: Interleukin-7 (IL-7) is important for the growth and resistance to chemotherapy of T-cell acute lymphoblastic leukemia (T-ALL), especially the early T-cell precursor subtype (ETP-ALL). Signal transducer and activator of transcription (STAT5) is universally activated in ETP-ALL and plays a crucial role in its development. Inhibition of STAT5 is necessary to block the supportive signals provided by IL-7 and eradicate leukemia stem cells (LSCs).
Article Oncology

In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts

Joanna Randall, Kathryn Evans, Ben Watts, Christopher M. M. Smith, Keira Hughes, Eric J. J. Earley, Stephen W. W. Erickson, Jonathan A. A. Pachter, Beverly A. A. Teicher, Malcolm A. A. Smith, Richard B. B. Lock

Summary: Acute lymphoblastic leukemia (ALL) is a common cause of cancer-related mortality in children. The PI3K pathway has been associated with ALL, and duvelisib has shown efficacy as a dual inhibitor of PI3K delta and PI3K gamma. In this study, duvelisib demonstrated limited in vivo activity against pediatric ALL patient-derived xenografts (PDXs).

PEDIATRIC BLOOD & CANCER (2023)

Article Oncology

In vivo activity of the dual SYK/FLT3 inhibitor TAK-659 against pediatric acute lymphoblastic leukemia xenografts

Keira Hughes, Kathryn Evans, Eric J. Earley, Christopher M. Smith, Stephen W. Erickson, Tim Stearns, Vivek M. Philip, Steven B. Neuhauser, Jeffrey H. Chuang, Emily L. Jocoy, Carol J. Bult, Beverly A. Teicher, Malcolm A. Smith, Richard B. Lock

Summary: Although the majority of children with acute lymphoblastic leukemia (ALL) can be cured, certain high-risk subtypes of pediatric ALL have poor treatment outcomes. This study investigated the in vivo efficacy of TAK-659 in patient-derived xenografts (PDXs) of pediatric ALL. The results showed that TAK-659 prolonged the time to event in six out of eight PDXs tested, but only one PDX achieved an objective response.

PEDIATRIC BLOOD & CANCER (2023)

Article Multidisciplinary Sciences

Menin reads H3K79me2 mark in a nucleosomal context

Jianwei Lin, Yiping Wu, Gaofei Tian, Daqi Yu, Eunjeong Yang, Wai Hei Lam, Zheng Liu, Yihang Jing, Shangyu Dang, Xiucong Bao, Jason Wing Hon Wong, Yuanliang Zhai, Xiang David Li

Summary: H3K79me2 is an important epigenetic mark involved in gene regulation, cellular differentiation, and disease progression. A nucleosome-based photoaffinity probe was used to identify menin as a reader of H3K79me2 in a nucleosomal context. Cryo-electron microscopy showed that menin interacts with the nucleosome through specific domains and recognizes the methylation mark through a p-cation interaction. In cells, menin is selectively associated with H3K79me2 on chromatin, particularly in gene bodies.

SCIENCE (2023)

Article Biochemistry & Molecular Biology

Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies

Zacary P. Germon, Jonathan R. Sillar, Abdul Mannan, Ryan J. Duchatel, Dilana Staudt, Heather C. Murray, Izac J. Findlay, Evangeline R. Jackson, Holly P. McEwen, Alicia M. Douglas, Tabitha McLachlan, John E. Schjenken, David A. Skerrett-Byrne, Honggang Huang, Marcella N. Melo-Braga, Maximilian W. Plank, Frank Alvaro, Janis Chamberlain, Geoff De Iuliis, R. John Aitken, Brett Nixon, Andrew H. Wei, Anoop K. Enjeti, Yizhou Huang, Richard B. Lock, Martin R. Larsen, Heather Lee, Vijesh Vaghjiani, Jason E. Cain, Charles E. de Bock, Nicole M. Verrills, Matthew D. Dun

Summary: Mutations in FLT3 gene are common in AML patients and associated with poor prognosis. This study found that oxidative stress affects growth and proliferation signaling pathways in FLT3 mutant AML. Inhibition of NOX2, an ROS-producing complex, increased apoptosis of FLT3-mutant AML cells. In mouse models, NOX2 inhibition reduced circulating cancer cells and combined treatment with NOX2 and FLT3 inhibitors improved survival.

SCIENCE SIGNALING (2023)

Article Cell Biology

Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia

Ernest Moles, Christopher B. Howard, Pie Huda, Mawar Karsa, Hannah McCalmont, Kathleen Kimpton, Alastair Duly, Yongjuan Chen, Yizhou Huang, Melinda L. Tursky, David Ma, Sonia Bustamante, Russell Pickford, Patrick Connerty, Sofia Omari, Christopher J. Jolly, Swapna Joshi, Sylvie Shen, John E. Pimanda, Alla Dolnikov, Laurence C. Cheung, Rishi S. Kotecha, Murray D. Norris, Michelle Haber, Charles E. de Bock, Klaartje Somers, Richard B. Lock, Kristofer J. Thurecht, Maria Kavallaris

Summary: High-risk childhood leukemia has a poor prognosis due to treatment failure and toxic side effects. Encapsulation of drugs in liposomal nanocarriers improves biodistribution and tolerability, but lacks selectivity for cancer cells. In this study, bispecific antibodies were generated to target PEGylated liposomal drugs to leukemic cells. These antibodies improved targeting and cytotoxic activity, with minimal harm to normal cells. Targeted delivery using bispecific antibodies enhanced leukemia suppression and extended overall survival, representing a promising platform for improved treatment of high-risk leukemia.

SCIENCE TRANSLATIONAL MEDICINE (2023)

Article Cell Biology

The tip of the iceberg-The roles of long noncoding RNAs in acute myeloid leukemia

Patrick Connerty, Richard B. Lock

Summary: Long noncoding RNAs (lncRNAs), defined as RNA transcripts longer than 200 nucleotides with no protein coding potential, have been found to be dysregulated in various cancers, including acute myeloid leukemia (AML). As survival rates for AML have plateaued, the identification of lncRNAs as novel biomarkers and therapeutic targets for AML is crucial. This review assesses key studies that have identified lncRNAs in AML and summarizes the current knowledge of their roles, including driving proliferation, differentiation block, therapy resistance, tumor suppression, and utility as biomarkers.

WILEY INTERDISCIPLINARY REVIEWS-RNA (2023)

Article Multidisciplinary Sciences

Integrative processing of untargeted metabolomic and lipidomic data using MultiABLER

Ian C. H. Lee, Sergey Tumanov, Jason W. H. Wong, Roland Stocker, Joshua W. K. Ho

Summary: Mass spectrometry-based untargeted metabolomic and lipidomic approaches are widely used in biomedical research. A sample extraction method called Multi-ABLE has been developed for concurrent generation of proteomic, metabolomic, and lipidomic data. However, there is a lack of a unified bioinformatics pipeline for processing and analysis of these data. A new R pipeline called MultiABLER is presented here as a unified and simple upstream processing and analysis pipeline for metabolomics and lipidomics datasets.

ISCIENCE (2023)

Article Health Care Sciences & Services

The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours

Aya El Helali, Tai-Chung Lam, Elaine Yee-Ling Ko, David J. H. Shih, Chun Kau Chan, Charlene H. L. Wong, Jason W. H. Wong, Lydia W. T. Cheung, Johnny K. S. Lau, Anthony P. Y. Liu, Ann S. Y. Chan, Herbert H. Loong, Stephen Tak Sum Lam, Godfrey Chi-Fung Chan, Victor H. F. Lee, Kwok Keung Yuen, Wai-Tong Ng, Anne W. M. Lee, Edmond S. K. Ma

Summary: This study investigated the feasibility of the HKU-HKSH Multi-disciplinary Molecular Tumour Board (MTB) in determining genome-guided therapy for treatment-refractory solid cancers in Hong Kong. The results showed that MTB-guided treatment positively impacted patients' overall survival, illustrating the applicability of next-generation sequencing comprehensive gene profiling (CGP) in real-world clinical practice.

LANCET REGIONAL HEALTH-WESTERN PACIFIC (2023)

Article Oncology

High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

Chelsea Mayoh, Jie Mao, Jinhan Xie, Gabor Tax, Shu-Oi Chow, Roxanne Cadiz, Karina Pazaky, Paulette Barahona, Pamela Ajuyah, Peter Trebilcock, Angela Malquori, Kate Gunther, Anica Avila, Doo Young Yun, Stephanie Alfred, Anjana Gopalakrishnan, Alvin Kamili, Marie Wong, Mark J. Cowley, Sophie Jessop, Loretta M. S. Lau, Toby N. Trahair, David S. Ziegler, Jamie I. Fletcher, Andrew J. Gifford, Maria Tsoli, Glenn M. Marshall, Michelle Haber, Vanessa Tyrrell, Timothy W. Failes, Greg M. Arndt, Richard B. Lock, Paul G. Ekert, M. Emmy M. Dolman

Summary: One-third of pediatric cancer patients enrolled in precision medicine programs do not receive therapeutic recommendations from molecular profiling. In order to find potential strategies for treating high-risk pediatric patients, a study conducted in vitro screening of 125 patient-derived samples against a library of 126 anticancer drugs. The results showed that high-throughput drug screening (HTS) can identify effective biomarker-driven therapeutic strategies for high-risk pediatric cancers.

CANCER RESEARCH (2023)

Article Oncology

PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia

Kinjal Shah, Ahmad Nasimian, Mehreen Ahmed, Lina Al Ashiri, Linn Denison, Wondossen Sime, Katerina Bendak, Iryna Kolosenko, Valentina Siino, Fredrik Levander, Caroline Palm-Apergi, Ramin Massoumi, Richard B. Lock, Julhash U. Kazi

Summary: Deregulation of BCL2 family proteins is critical in leukemia development, and inhibiting these proteins has become a common treatment for the disease. However, resistance to this treatment has compromised its effectiveness. In this study, a drug sensitivity prediction model was developed to assess the sensitivity of T-cell acute lymphoblastic leukemia (T-ALL) patients to the drug venetoclax. The results showed that PLK1 is a cooperating partner for the BCL2-mediated antiapoptotic program, and concurrent treatment using venetoclax and PLK1 inhibitors demonstrated a greater therapeutic effect on T-ALL.

BLOOD CANCER JOURNAL (2023)

Article Oncology

Tumour mutational burden is overestimated by target cancer gene panels

Hu Fang, Johanna Bertl, Xiaoqiang Zhu, Tai Chung Lam, Song Wu, David J. H. Shih, Jason W. H. Wong

Summary: Tumour mutational burden (TMB) is a predictive marker for immune checkpoint inhibitor (ICI) responsiveness, but its calculation using different genomic regions is unclear. This study found that cancer gene-based panels usually overestimate TMB compared to whole exome, potentially leading to misclassification of patients for ICI treatment. A statistical model was developed to unify TMB calculations and improve patient stratification for ICI treatment.

JOURNAL OF THE NATIONAL CANCER CENTER (2023)

Article Materials Science, Multidisciplinary

Small zinc doped iron oxide tracers for magnetic particle imaging

H. T. Kim Duong, Ashkan Abdibastami, Lucy Gloag, Andre Bongers, Saeed Shanehsazzadeh, Melanie Nelson, Aidan Cousins, Narges Bayat, Hannah Mccalmont, Richard B. Lock, Scott Sulway, Joanna Biazick, J. Justin Gooding, Richard D. Tilley

Summary: Magnetic particle imaging (MPI) has gained attention in biomedical imaging research due to its excellent signal intensity. This study demonstrated zinc doped iron oxide nanoparticles as excellent tracers for MPI, with significant enhancement in saturation magnetisation and MPI signal intensity compared to traditional iron oxide nanoparticles.

JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS (2023)

暂无数据